Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering

被引:6
作者
Legrand, Pauline [1 ,2 ]
Dufay, Sophie [2 ]
Mignet, Nathalie [1 ]
Houze, Pascal [1 ,3 ]
Gahoual, Rabah [1 ]
机构
[1] Univ Paris Cite, Fac Sci Pharmaceut & Biol, Unite Technol Chim & Biol Sante UTCBS, CNRS UMR8258,Inserm U1267, 4,Ave Observ, F-75270 Paris 06, France
[2] Agence Gen Equipements & Produits Sante AGEPS, Assistance Publ Hop Paris AP HP, Dept Rech & Dev Pharmaceut, Paris, France
[3] Hop Lariboisiere, Assistance Publ Hop Paris AP HP, Lab Toxicol Biol, Paris, France
关键词
Monoclonal antibody; Biosimilar; Stability study; Stability modeling; Mass spectrometry; Multi-angle light scattering; FORCED DEGRADATION; ACCELERATED STABILITY; ASSESSMENT PROGRAM; DRUGS; REMICADE(R); QUALITY; STRESS;
D O I
10.1007/s00216-022-04396-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Monoclonal antibodies (mAbs) represent a dynamic class of biopharmaceutical products, as evidenced by an increasing number of market authorizations for mAb innovator and biosimilar products. Stability studies are commonly performed during product development, for instance, to exclude unstable molecules, optimize the formulation or determine the storage limit. Such studies are time-consuming, especially for mAbs, because of their structural complexity which requires multiple analytical techniques to achieve a detailed characterization. We report the implementation of a novel methodology based on the accelerated stability assessment program (ASAP) in order to model the long-term stability of mAbs in relation to different structural aspects. Stability studies of innovator infliximab and two different biosimilars were performed using forced degradation conditions alongside in-use administration conditions in order to investigate their similarity regarding stability. Thus, characterization of post-translational modifications was achieved using liquid-chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and the formation of aggregates and free chain fragments was characterized using size-exclusion chromatography-multi-angle light scattering (SEC-MALS-UV/RI) analysis. Consequently, ASAP models were investigated with regard to free chain fragmentation of mAbs concomitantly with N57 deamidation, located in the hypervariable region. Comparison of ASAP models and the long-term stability data from samples stored in intravenous bags demonstrated a relevant correlation, indicating the stability of the mAbs. The developed methodology highlighted the particularities of ASAP modeling for mAbs and demonstrated the possibility to independently consider the different types of degradation pathways in order to provide accurate and appropriate prediction of the long-term stability of this type of biomolecule.
引用
收藏
页码:179 / 192
页数:14
相关论文
共 45 条
  • [1] Determination of critical quality attributes for monoclonal antibodies using quality by design principles
    Alt, Nadja
    Zhang, Taylor Y.
    Motchnik, Paul
    Taticek, Ron
    Quarmby, Valerie
    Schlothauer, Tilman
    Beck, Hermann
    Emrich, Thomas
    Harris, Reed J.
    [J]. BIOLOGICALS, 2016, 44 (05) : 291 - 305
  • [2] [Anonymous], 2014, GUIDELINE SIMILAR BI
  • [3] Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
    Beck, Alain
    D'Atri, Valentina
    Ehkirch, Anthony
    Fekete, Szabolcs
    Hernandez-Alba, Oscar
    Gahoual, Rabah
    Leize-Wagner, Emmanuel
    Francois, Yannis
    Guillarme, Davy
    Cianferani, Sarah
    [J]. EXPERT REVIEW OF PROTEOMICS, 2019, 16 (04) : 337 - 362
  • [4] Characterization of Therapeutic Antibodies and Related Products
    Beck, Alain
    Wagner-Rousset, Elsa
    Ayoub, Daniel
    Van Dorsselaer, Alain
    Sanglier-Cianferani, Sarah
    [J]. ANALYTICAL CHEMISTRY, 2013, 85 (02) : 715 - 736
  • [5] Strategies and challenges for the next generation of therapeutic antibodies
    Beck, Alain
    Wurch, Thierry
    Bailly, Christian
    Corvaia, Nathalie
    [J]. NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) : 345 - 352
  • [6] Blessy M, 2014, J Pharm Anal, V4, P159, DOI 10.1016/j.jpha.2013.09.003
  • [7] Colgan ST, 2018, ACCELERATED PREDICTIVE STABILITY (APS): FUNDAMENTALS AND PHARMACEUTICAL INDUSTRY PRACTICES, P15, DOI 10.1016/B978-0-12-802786-8.00002-4
  • [8] Bispecific antibody characterization by a combination of intact and site-specific/chain-specific LC/MS techniques
    Duivelshof, Bastiaan L.
    Beck, Alain
    Guillarme, Davy
    D'Atri, Valentina
    [J]. TALANTA, 2022, 236
  • [9] Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment
    Dyck, Yan Felix Karl
    Rehm, Daniel
    Joseph, Jan Felix
    Winkler, Karsten
    Sandig, Volker
    Jabs, Wolfgang
    Parr, Maria Kristina
    [J]. BIOENGINEERING-BASEL, 2019, 6 (03):
  • [10] Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling
    Evers, Andreas
    Clenet, Didier
    Pfeiffer-Marek, Stefania
    [J]. PHARMACEUTICS, 2022, 14 (02)